Previous close | 96.00 |
Open | 96.72 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 96.00 - 96.00 |
52-week range | 90.12 - 109.00 |
Volume | |
Avg. volume | 44,208 |
Market cap | 199.437B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 21.82 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.76 (3.92%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), Cosentyx (+25% cc), Kesimpta (+66% cc), Kisqali (+54% cc), Pluvicto (+47% cc) and Leqvio (+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net salesOperating income grew +39% (cc, +29% USD) and net income grew +37% (cc, +25% USD), mainly driven